Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Stock Short Interest Climbs 58.7%

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 81,750 shares, a growth of 58.7% from the September 15th total of 51,519 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 438,330 shares, the days-to-cover ratio is currently 0.2 days.

Chugai Pharmaceutical Price Performance

Chugai Pharmaceutical stock traded down $0.01 during midday trading on Friday, hitting $19.96. 2,276,211 shares of the company were exchanged, compared to its average volume of 349,816. The company has a market cap of $65.70 billion, a PE ratio of 21.70 and a beta of 0.60. Chugai Pharmaceutical has a fifty-two week low of $18.33 and a fifty-two week high of $34.84. The company’s fifty day moving average price is $20.90 and its 200-day moving average price is $23.15.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. On average, analysts expect that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CHGCY. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.